1
|
Tingry T, Massy E, Piperno M, Auroux M, Kostine M, Maillet D, Amini-Adle M, Fabien N, Estublier C, Goncalves D, Girard N, Confavreux CB. [Rheumatic immune adverse events related to immune checkpoint inhibitors-(IrAEs related to ICI)]. Bull Cancer 2021; 108:643-653. [PMID: 33902919 DOI: 10.1016/j.bulcan.2021.01.016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2019] [Revised: 01/12/2021] [Accepted: 01/20/2021] [Indexed: 12/17/2022]
Abstract
New anti-cancer therapeutics have been developed in the recent years and dramatically change prognosis and patient management. Either used alone or in combination, immune checkpoint inhibitors (ICI), such as anti-CTLA-4 and anti-PD1/PD-(L)1, act by removing T-cell inhibition to enhance their antitumor response. This change in therapeutic targets leads to a break in immune-tolerance and a unique toxicity profile resulting in immune complications. These side effects, called Immune-Related Adverse Events (IrAEs), can affect all organs, with a wide range of clinical and biological presentations and severity. Various rheumatic and musculoskeletal manifestations have been reported in the literature, ranging from mild arthralgia, polymyalgia rheumatica, to genuine serodefined rheumatoid arthritis and myositis. Tolerance studies suggest some correlations between IrAEs occurrence and tumor response. Assessment of patient musculoskeletal status prior to the start of the ICI is warranted. Management of rheumatic IrAEs does not usually request ICI discontinuation, exception for myositis or very severe forms where it should be discussed. Treatment relies on non-steroidal anti-inflammatory drugs (NSAIDs) or low dose glucocortioids (<20mg per day). Dose should be adjusted according to severity. The use of disease modifying anti-rheumatic drugs (DMARDs), either conventional and/or biological should be very cautious and result from a shared decision between oncologist and rheumatologist to best manage dysimmunitary complications without hampering the antitumor efficacy of ICI.
Collapse
Affiliation(s)
- Thomas Tingry
- Centre hospitalier Lyon Sud-hospices civils de Lyon, service de rhumatologie, centre expert des métastases et d'oncologie osseuse secondaire (CEMOS), 69310 Pierre Bénite, France; Université de Lyon, Inserm UMR 1033-LYOS, 69003 Lyon, France; Institut de cancérologie des hospices Civils de Lyon, ImmuCare (Immunology cancer research), 69310 Pierre Bénite, France
| | - Emmanuel Massy
- Centre hospitalier Lyon Sud-hospices civils de Lyon, service de rhumatologie, centre expert des métastases et d'oncologie osseuse secondaire (CEMOS), 69310 Pierre Bénite, France; Université de Lyon, Inserm UMR 1033-LYOS, 69003 Lyon, France; Institut de cancérologie des hospices Civils de Lyon, ImmuCare (Immunology cancer research), 69310 Pierre Bénite, France
| | - Muriel Piperno
- Centre hospitalier Lyon Sud-hospices civils de Lyon, service de rhumatologie, centre expert des métastases et d'oncologie osseuse secondaire (CEMOS), 69310 Pierre Bénite, France; Institut de cancérologie des hospices Civils de Lyon, ImmuCare (Immunology cancer research), 69310 Pierre Bénite, France
| | - Maxime Auroux
- Centre hospitalier Lyon Sud-hospices civils de Lyon, service de rhumatologie, centre expert des métastases et d'oncologie osseuse secondaire (CEMOS), 69310 Pierre Bénite, France
| | - Marie Kostine
- Centre hospitalier universitaire de Bordeaux, département de rhumatologie, 33000 Bordeaux, France
| | - Denis Maillet
- Institut de cancérologie des hospices Civils de Lyon, ImmuCare (Immunology cancer research), 69310 Pierre Bénite, France; Centre Hospitalier Lyon Sud, Hospices civils de Lyon, service d'oncologie médicale, 69310 Pierre Bénite, France
| | - Mona Amini-Adle
- Institut de cancérologie des hospices Civils de Lyon, ImmuCare (Immunology cancer research), 69310 Pierre Bénite, France; Centre de lutte contre le cancer Léon-Bérard, service de dermatologie, 69003 Lyon, France
| | - Nicole Fabien
- Centre Hospitalier Lyon Sud, hospices civils de Lyon, laboratoire d'auto-immunité, 69310 Pierre Bénite, France
| | - Charline Estublier
- Centre hospitalier Lyon Sud-hospices civils de Lyon, service de rhumatologie, centre expert des métastases et d'oncologie osseuse secondaire (CEMOS), 69310 Pierre Bénite, France; Université de Lyon, Inserm UMR 1033-LYOS, 69003 Lyon, France; Institut de cancérologie des hospices Civils de Lyon, ImmuCare (Immunology cancer research), 69310 Pierre Bénite, France
| | - David Goncalves
- Centre Hospitalier Lyon Sud, hospices civils de Lyon, laboratoire d'auto-immunité, 69310 Pierre Bénite, France
| | - Nicolas Girard
- Institut Curie, institut du Thorax Curie Montsouris, 75005 Paris, France
| | - Cyrille B Confavreux
- Centre hospitalier Lyon Sud-hospices civils de Lyon, service de rhumatologie, centre expert des métastases et d'oncologie osseuse secondaire (CEMOS), 69310 Pierre Bénite, France; Université de Lyon, Inserm UMR 1033-LYOS, 69003 Lyon, France; Institut de cancérologie des hospices Civils de Lyon, ImmuCare (Immunology cancer research), 69310 Pierre Bénite, France.
| |
Collapse
|
2
|
Villiger E, Grandinetti T, Tamborrini G. [Rheumatology from A to Z - a Web-Based Information Tool]. Praxis (Bern 1994) 2019; 108:609-614. [PMID: 31288660 DOI: 10.1024/1661-8157/a003259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Rheumatology from A to Z - a Web-Based Information Tool Abstract. Online health information is consulted frequently. However, appropriately examining this data for its quality, trustworthiness, and clinical relevance presents a challenge even for medical professionals. This project offers contents in the area of the musculoskeletal system that has been compiled and verified by experts. Overall, 222 terms are defined, explained and equipped with clinically relevant details in order to provide interested professionals with quick and encompassing access to high-quality, subject-specific information. In addition, these terms are supplemented with a total of 2150 links to websites of verified quality with further information. All content is provided in English and German and can be retrieved either by website or by app.
Collapse
Affiliation(s)
| | | | - Giorgio Tamborrini
- 3 Ultraschallzentrum Rheumatologie Basel und Konsiliararzt Universitätsspital Basel
| |
Collapse
|
3
|
Buzelé R, Lemaignen A, Gras G, Bernard L. [Vertebral osteomyelitis: to suspect ahead any inflammatory spinal pain]. Rev Prat 2016; 66:893-898. [PMID: 30512545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Vertebral osteomyelitis: to suspect ahead any inflammatory spinal pain. Infectious vertebral osteomyelitis is a rare and severe condition with potential septic, neurologic or mechanical complications and a lethality of about 10%. Clinical diagnosis is difficult and delay in management is frequent. Diagnosis confirmation relies on MRI and microbiological documentation by blood cultures and/or image-guided percutaneous vertebral biopsy. Adapted antibiotic therapy during 6 weeks is the mainstay of treatment, with fast oral relay. Associated treatments include a short rest, initial immobilization, analgesia and sometimes surgery. Outcome is usually favorable. Adverse evolution is mainly associated with age and comorbidities, and to a less extent to presence of neurological impairment, Staphylococcus aureus and diagnosis delay.
Collapse
Affiliation(s)
- Rodolphe Buzelé
- Service de médecine interne et maladies infectieuses, CHRU de Tours. Université François Rabelais - Faculté de médecine de Tours-Centre de référence de prise en charge des infections ostéo-articulaires du Grand-Ouest (CRIOGO)
| | - Adrien Lemaignen
- Service de médecine interne et maladies infectieuses, CHRU de Tours. Université François Rabelais - Faculté de médecine de Tours-Centre de référence de prise en charge des infections ostéo-articulaires du Grand-Ouest (CRIOGO)
| | - Guillaume Gras
- Service de médecine interne et maladies infectieuses, CHRU de Tours. Université François Rabelais - Faculté de médecine de Tours-Centre de référence de prise en charge des infections ostéo-articulaires du Grand-Ouest (CRIOGO)
| | - Louis Bernard
- Service de médecine interne et maladies infectieuses, CHRU de Tours. Université François Rabelais - Faculté de médecine de Tours-Centre de référence de prise en charge des infections ostéo-articulaires du Grand-Ouest (CRIOGO)
| |
Collapse
|
4
|
Hilliquin P, Zalc J. [What's new in rheumatology]. Rev Prat 2016; 66:869-873. [PMID: 30512541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Affiliation(s)
- Pascal Hilliquin
- Service de rhumatologie, centre hospitalier Sud-Francilien, Corbeil-Essonnes, France
- Laboratoire Genhotel, Génopole, Évry, France
| | - Jordan Zalc
- Service de rhumatologie, centre hospitalier Sud-Francilien, Corbeil-Essonnes, France
| |
Collapse
|
5
|
Portier A, Rajzbaum G. [Cervicobrachial neuralgia: frequent and sometimes very painful]. Rev Prat 2016; 66:549-554. [PMID: 30512580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Cervicobrachial neuralgia. Cervicobrachial neuralgia is a common reason of rheumatologist consultation. It can be defined as cervicalgia associated with radicular pain of the upper limb, caused by a nerve compression. The most frequent cause is a soft disc herniation. Gravity signs have to be researched by a methodic physical exam: neurological deficit, medullar compression. Imagery is recommended: X-rays, tomodensitometry and/or MRI of cervical spine. The treatment is a combination of medicinal and non medicinal therapies, and in some cases, a surgical intervention is required.
Collapse
Affiliation(s)
- Agnes Portier
- Service de rhumatologie, Groupe hospitalier Paris-Saint-Joseph, Paris, France
| | - Gerald Rajzbaum
- Service de rhumatologie, Groupe hospitalier Paris-Saint-Joseph, Paris, France
| |
Collapse
|
6
|
Roux F, Lons Danic D. [Psoriatic arthritis, a difficult diagnosis due to clinical polymorphism]. Rev Prat 2016; 66:527-532. [PMID: 30512577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Psoriatic arthritis, a difficult diagnosis due to clinical polymorphism. Psoriatic arthritis (PsA) is a chronic inflammatory spondyloarthritis that occurs in combination with psoriasis. The prevalence is similar to rheumatoid arthritis. The diagnosis is difficult because the disease is heterogeneous, involving skin, nails and different musculoskeletal structures. There are no pathognomonic serological marker. Psoriasis usually appears 5-10 years before PsA, although some patients presents with PsA without psoriasis. TNF inhibitors (tumor necrosis factor: biological agents) have revolutionized therapy for PsA; there are effective against all disease characteristics, however not all patients achieve clinically meaningful responses and some may respond initially but lose treatment responses over time. With a better understanding of immunological mechanisms underlying psoriasis and PsA, new therapies have been developed to target specific components of the inflammatory pathway. IL17-17A and IL23 inhibitors agents (Th 17-IL17A pathway) has been shown to be efficacious. PsA is associated with a premature mortality, increased cardio vascular morbidity, obesity, metabolic syndrome. Collaboration between rheumatologist, dermatologist and general practitioner for the evaluation of morbidities, is be necessary in managing patients with PsA.
Collapse
|